Skip to content

Study · Systematic review · 2015

6 results

Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis.

Sun F, Wu S, Guo S, Yu K, Yang Z, Li L, Zhang Y, Quan X, Ji L, Zhan S

Diabetes research and clinical practice13 Aug 2015Cited by 255 (Europe PMC)

PMID26358202 (opens in a new tab)DOI10.1016/j.diabres.2015.07.015 (opens in a new tab)PepBankPUB-26358202
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanSystematic reviewSafety outcome

    In patients with type 2 diabetes, liraglutide 1.2 mg once daily increased heart rate by 2.06 beats/min versus placebo.

    In plain wordsIn patients with type 2 diabetes, liraglutide 1.2 mg once daily raised heart rate slightly compared with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseHeart rate with liraglutide 1.2 mg once daily
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.2 mg once dailyAs given in this study (human).

    Measurements

    heart rate increase
    2.06 beats/min
    liraglutide 1.2 mg once daily

    Source sentences

    Summary
    Exenatide (2 mg once weekly), liraglutide 1.2 mg once daily), and liraglutide (1.8 mg once daily) increased heart rate by 3.35 (95% CI: 1.23-5.50), 2.06 (95% CI: 0.43, 3.74), and 2.35 (95% CI: 0.94-3.76) beats/min versus placebo.
    1 context sentence
    Summary · context
    Randomized-controlled trials with available data were included if they compared GLP-1RAs with placebo and traditional antidiabetic drugs in patients with type 2 diabetes with duration ≥ 12 weeks.
  2. 02HumanSystematic reviewSafety outcome

    In patients with type 2 diabetes, liraglutide 1.8 mg once daily increased heart rate by 2.35 beats/min versus placebo.

    In plain wordsIn patients with type 2 diabetes, liraglutide 1.8 mg once daily raised heart rate slightly compared with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseHeart rate with liraglutide 1.8 mg once daily
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.8 mg once dailyAs given in this study (human).

    Measurements

    heart rate increase
    2.35 beats/min
    liraglutide 1.8 mg once daily

    Source sentences

    Summary
    Exenatide (2 mg once weekly), liraglutide 1.2 mg once daily), and liraglutide (1.8 mg once daily) increased heart rate by 3.35 (95% CI: 1.23-5.50), 2.06 (95% CI: 0.43, 3.74), and 2.35 (95% CI: 0.94-3.76) beats/min versus placebo.
    1 context sentence
    Summary · context
    Randomized-controlled trials with available data were included if they compared GLP-1RAs with placebo and traditional antidiabetic drugs in patients with type 2 diabetes with duration ≥ 12 weeks.

Studies that did not test the peptide alone4

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 03HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In patients with type 2 diabetes, the heart rate increase seen with the GLP-1 receptor agonists was also evident compared with active control (range 2.22-3.62).

    In plain wordsIn patients with type 2 diabetes, GLP-1 drugs as a group raised heart rate slightly compared with other diabetes drugs.

    Peptide
    Liraglutide
    Outcome
    IncreaseHeart rate versus active control (pooled GLP-1RAs)
    Study

    n: not reported in source

    Comparator
    Active control
    Outcome group
    Heart function · Cardiovascular

    Measurements

    heart rate increase
    2.22 to 3.62 beats/min
    versus active control

    Source sentences

    Summary
    This effect was evident compared with active control (range: 2.22-3.62).
    1 context sentence
    Summary · context
    Randomized-controlled trials with available data were included if they compared GLP-1RAs with placebo and traditional antidiabetic drugs in patients with type 2 diabetes with duration ≥ 12 weeks.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In patients with type 2 diabetes, pooled GLP-1 receptor agonists decreased systolic blood pressure compared with placebo, insulin and sulfonylureas (range -1.84 to -4.60 mmHg).

    In plain wordsIn patients with type 2 diabetes, GLP-1 drugs as a group lowered systolic blood pressure compared with placebo, insulin and sulfonylureas.

    Peptide
    Liraglutide
    Outcome
    DecreaseSystolic blood pressure (pooled GLP-1RAs)
    Study

    n: not reported in source

    Comparator
    Placebo, insulin and sulfonylureas
    Outcome group
    Blood pressure · Cardiovascular

    Measurements

    systolic blood pressure change
    −4.6 to −1.84 mmHg
    GLP-1RAs versus comparators

    Source sentences

    Summary
    Compared with placebo, insulin, and sulfonylureas, GLP-1RAs decreased systolic blood pressure with range from -1.84 mmHg (95% CI: -3.48 to -0.20) to -4.60 mmHg (95% CI: -7.18 to -2.03).
    1 context sentence
    Summary · context
    Randomized-controlled trials with available data were included if they compared GLP-1RAs with placebo and traditional antidiabetic drugs in patients with type 2 diabetes with duration ≥ 12 weeks.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In patients with type 2 diabetes, a reduction in diastolic blood pressure versus placebo was detected significantly only for exenatide 10 μg twice daily among the GLP-1 receptor agonists.

    In plain wordsIn patients with type 2 diabetes, among GLP-1 drugs only exenatide twice daily clearly lowered diastolic blood pressure versus placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeDiastolic blood pressure (GLP-1RAs)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular

    Source sentences

    Summary
    Compared with placebo, a reduction in diastolic blood pressure was detected significantly only for exenatide-10 μg-twice-daily (-1.08 mmHg, 95% CI: -1.78 to -0.33).
    1 context sentence
    Summary · context
    Randomized-controlled trials with available data were included if they compared GLP-1RAs with placebo and traditional antidiabetic drugs in patients with type 2 diabetes with duration ≥ 12 weeks.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 06HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In patients with type 2 diabetes, no significant association between incident hypertension and GLP-1 receptor agonists was detected, except for exenatide 10 μg twice daily versus sulfonylureas.

    In plain wordsIn patients with type 2 diabetes, GLP-1 drugs as a group were not linked to new high blood pressure.

    Peptide
    Liraglutide
    Outcome
    No significant changeIncident hypertension (GLP-1RAs)
    Study

    n: not reported in source

    Comparator
    Placebo and traditional antidiabetic drugs
    Outcome group
    Blood pressure · Cardiovascular

    Source sentences

    Summary
    No significant association between incident hypertension and GLP-1RAs was detected, except for the association between exenatide-10 μg-twice-daily and sulfonylureas (OR, 0.40, 95% CI: 0.16, 0.82).
    1 context sentence
    Summary · context
    Randomized-controlled trials with available data were included if they compared GLP-1RAs with placebo and traditional antidiabetic drugs in patients with type 2 diabetes with duration ≥ 12 weeks.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.